Acquisition advantage Cyprotex is an Evotec-owned ADME-Tox specialist with established US and UK sites, indicating a ready-made network and parent-backed scale that can accelerate engagements for pharmaceutical, biotech, and CRO partners needing ADME-Tox and in vitro/in silico services.

Expanded service suite Offering high-throughput ADME screening, customized ADME assays, in silico ADME modeling, in vitro toxicology, and transcriptomics positions Cyprotex to cross-sell a broad portfolio to clients seeking end-to-end ADME-Tox solutions and data integration.

Digital ordering The launch of an e-store for online ordering simplifies procurement for customers, suggesting clear upsell opportunities for repeat business, faster project kickoffs, and potential for bundled service offerings and volume discounts.

US presence optimization Recent office relocation in Massachusetts underscores a focus on expanding U.S. client access; market opportunity exists to target biopharma firms in New England and the broader U.S. market with ADME-Tox services and rapid-turnaround studies.

Growth through Evotec As part of the Evotec Group, Cyprotex can leverage cross-company collaborations, preferred-partner status, and combined capabilities to pursue joint programs, milestone-based contracts, and data-sharing opportunities with Evotec’s extensive client base.